RemeGen   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Yantai China (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2015
NCT02882087
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

RemeGen | RemeGen Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Biliary Tract Neoplasms (Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Kidney Diseases (Phase 2)

Lung Neoplasms (Phase 2)

Lupus Erythematosus, Systemic (Phase 3)

Macular Degeneration (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Neoplasms (Phase 1)

Neuromyelitis Optica (Phase 3)

Sclerosis (Phase 2)

Sjogren's Syndrome (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 41
  • # of Trial APIs: 22